DNA chips are quickly becoming commodity. The profit business is the regeant and service part. It is like razor and blade story again. Affimetrix who pioneered DNA chips has market cap less than $500 mil. Ilumina has better technology (market cap $5 bil). The most efficient technology for genome sequence is not going to DNA chips.